Patent ID: 11859003
Assignee: ADAGENE, INC.
Field: Pharmaceuticals (Chemistry)
Classification: CPC A  C | IPC A  C

Claim 3:
4. The method of claim 2, wherein the at least one additional therapeutic agent is selected from the group consisting of lenalidomide, pomalidomide, thalidomide, a DNA-alkylating platinum-containing derivative, 5-fluorouracil, cyclophosphamide, an anti-CTLA4 antibody, an anti-PD-1 antibody, an anti-PD-L1 antibody, an anti-CD20 antibody, an anti-CD40 antibody, an anti-DR5 antibody, an anti-CD1d antibody, an anti-TIM3 antibody, an anti-SLAMF7 antibody, an anti-KIR receptor antibody, an anti-0X40 antibody, an anti-HER2 antibody, an anti-EGFR antibody, radiotherapy, IL-12, IFNα, GM-CSF, a chimeric antigen receptor, adoptively transferred T cells, an anti-cancer vaccine, and an oncolytic virus.